Clinical pharmacokinetic and metabolism of PET radiotracers for imaging P-glycoprotein in chemoresistant tumor of colorectal cancer

Current Drug Metabolism

Volumn 12, Issue 10, 2011, Pages 985-988

  Cantore, Mariangela ^a   Capparelli, Elena ^a   Berardi, Francesco ^a   Perrone, Roberto ^a   Colabufo, Nicola Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

11 C radiotracers; Colorectal cancer; Everted gut sac; MultiDrug Resistance; P glycoprotein; PET

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; TRACER; XENOBIOTIC AGENT;

ARTICLE; CELL MEMBRANE; COLORECTAL CANCER; GASTROINTESTINAL TUMOR; IN VIVO STUDY; KIDNEY; MULTIDRUG RESISTANCE; POSITRON EMISSION TOMOGRAPHY; TUMOR RESISTANCE;

ATP-BINDING CASSETTE TRANSPORTERS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 82255169473     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798062292     Document Type: Article

References (35)

1. Altemberg, G. A. Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily. Curr. Med. Chem., 2004, 4, 53-62.
2. Pérez-Tomás, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13, 1859-1876.
3. Giménez-Bonafé, P.; Guillén Canovas, A.; Ambrosio, S.; Tortosa, A.; Pérez-Tomás, R. In: Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment; Colabufo, N. A., Ed.; Research Signpost: Kerala, India, 2008; pp. 63-99.
4. Modok, S.; Mellor, H. R.; Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol, 2006, 6, 350-354. (Pubitemid 44026037)
5. Jendzelovsky, R.; Mikes, J.; Koval', J.; Soucek, K.; Prochá zková, J.; Kello, M.; Sacková, V.; Hofmanová, J.; Kozubík, A.; Fedorocko, P. Drug efflux transporters, MRP1 and BCRP, affect the out come of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem. Photobiol. Sci., 2009, 8, 1716-1723.
6. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 2001, 11, 1156.
7. Colabufo, N. A.; Berardi, F.; Contino, M.; Niso, M.; Perrone, R. ABC pumps and their role in active drug transport. Curr. Top. Med. Chem., 2009, 9, 119-129.
8. Zhou, S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38, 802-832.
9. Leslie, E. M.; Deeley, R. G.; Cole, S. P. C. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol., 2005, 204, 216-237. (Pubitemid 40552845)
10. Mao, Q.; Unadkat, J. D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J., 2005, 7, E118-133. (Pubitemid 41554295)
11. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. The multidrug resistance protein family. Biochim. Biophys. Acta., 1999, 1461, 347-357.
12. Wagner, C. C.; Langer, O. Approaches using molecular imaging technology - use of PET in clinical microdose studies. Adv. Drug Deliv. Rev., 2011, 63, 539-546.
13. Benet, L. Z.; Izumi, T.; Zhang, Y.; Silverman, J. A.; Wacher, V. J. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Controlled Release., 1999, 62, 25-31. (Pubitemid 29486478)
14. Colabufo, N. A.; Berardi, F.; Perrone, M. G.; Capparelli, E; Cantore, M.; Inglese, C.; Perrone, R. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr. Top. Med. Chem., 2010, 10, 1703-1714.
15. van Waarde, A.; Ramakrishnan, N.; Rybczynska, A.; Elsinga, P.; Berardi, F.; De Jong, J.; Kwizera, C.; Perrone, R.; Cantore, M.; Sijbesma, J.; Dierckx, R.; Colabufo, N. A. Synthesis and pre-clinical evaluation of novel PET probes for P-glycoprotein function and expression. J. Med. Chem., 2009, 52, 4524-4532.
16. Hendrikse, N. H.; de Vries, E. G. E.; Eriks, F. L.; van der Graaf, W. T. A.; Hospers, G. A. P.; Willemsen, A. T. M.; Vaalburg, W.; Franssen, E. J. F. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res., 1999, 59, 2411-2416. (Pubitemid 29242290)
17. Luurtsema, G.; Molthoff, C. F.; Windhorst, A. D.; Smit, J. W.; Keizer, H.; Boellaard, R.; Lammertsma, A. A.; Franssen, E. J. (R) - and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol., 2003, 30, 747-751. (Pubitemid 37123132)
18. Luurtsema, G.; Schuit, R. C.; Klok, R. P.; Verbeek, J.; Leysen, J. E.; Lammertsma, A. A.; Windhorst, A. D. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol., 2009, 36, 643-649.
19. 11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J. Med. Chem., 2009, 52, 6073-6082.
20. Yamasaki, T.; Kawamura, K.; Hatori, A.; Yui, J.; Yanamoto, K.; Yoshida, Y.; Ogawa, M.; Nengaki, N.; Wakisaka, H.; Fukumura, T.; Zhang, M. R. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein. Nucl. Med. Commun., 2010, 31, 985-993.
21. Bauer, F.; Kuntner, C.; Bankstah, J. P.; Wanek, T.; Bankstahl, M.; Stanek, J.; Mairinger, S.; Dörner, B.; Löscher, W.; Müller, M.; Erker, T.; Langer, O. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg. Med. Chem., 2010, 18, 5489-5497.
22. Luurtsema, G.; Verbeek, G. L.; Lubberink, M.; Lammertsma, A. A.; Dierckx, R.; Elsinga, P.; Windhorst, A. D.; van Waarde, A. Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages. Curr. Top. Med. Chem., 2010, 10, 1820-1833.
23. Dong, Z.; Ward, N. E.; Fan, D.; Gupta, K.; O'Brian, C. A. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol. Pharmacol., 1991, 39, 563-569.
24. Calcagno, A. M.; Ludwig, J. A.; Fostel, J. M.; Gottesman, M. M.; Ambudkar, S. V. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol. Pharm., 2006, 3, 87-93. (Pubitemid 43331755)
25. Dolfini, E.; Dasdia, T.; Arancia, G.; Molinari, A.; Calcabrini, A.; Scheper, R. J.; Flens, M. J.; Gariboldi, M. B.; Monti, E. Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Br. J. Cancer, 1997, 76, 67-76. (Pubitemid 27250078)
26. Hunter, J.; Jepson, M.; Tsuruo, T.; Simmons, N. L.; Hirst, B. H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem., 1993, 268, 14991-14997. (Pubitemid 23206648)
27. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. J. Pharmacol. Exp. Ther., 2001, 299, 620-628.
28. Canaparo, R.; Finnström, N.; Serpe, L.; Nordmark, A.; Muntoni, E.; Eandi, M.; Rane, A.; Zara, G. P. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin. Exp. Pharmacol. Physiol., 2007, 34, 1138-1144. (Pubitemid 47416351)
29. Chan, L. M.; Cooper, A. E.; Dudley, A. L.; Ford, D.; Hirst, B. H. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification. J. Drug Target, 2004, 12, 405-413. (Pubitemid 39562424)
30. Li, C.; Lee, M. Y.; Choi, J. S. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie, 2010, 65, 510-514.
31. Arellano, C.; Philibert, C.; Vachoux, C.; Woodley, J.; Houin, G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J. Pharm. Pharm. Sci., 2007, 10, 26-36. (Pubitemid 46647804)
32. Berruet, N.; Sentenac, S.; Auchere, D.; Gimenez, F.; Farinotti, R.; Fernandez, C. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J. Pharm. Pharm. Sci., 2005, 8, 226-234. (Pubitemid 41519136)
33. Barthe, L.; Bessouet, M.; Woodley, J. F.; Houin, G. The improved everted gut sac: a simple method to study intestinal P-glycoprotein. Int. J. Pharm., 1998, 173, 255-258.
34. Bouer, R.; Barthe, L.; Philibert, C.; Tournaire, C.; Woodley, J.; Houin, G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol., 1999, 13, 494-500. (Pubitemid 32250275)
35. Colabufo, N. A.; Berardi, F., Cantore, M.; Perrone, M. G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G. M.; Porcelli, L.; Paradiso, A. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem., 2008, 16, 362-373.